Other Information
−Removed: Not Applicable.
+Added: During the three months ended June 30, 2023, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
Incorporated by Reference
4 unchanged sentences
8-K 2/14/23 3.2
−Removed: 4.1 Specimen stock certificate evidencing the shares of common stock
−Removed: S-1/A 2/2/23 4.1
−Removed: 4.2 Amended and Restated Investors’ Rights Agreement, dated June 1, 2022, by and among the Registrant and certain of its stockholders
−Removed: S-1/A 2/2/23 4.2
−Removed: 10.1# Mineralys Therapeutics, Inc.
−Removed: Amended and Restated 2020 Equity Incentive Plan and form of stock option agreement and form of restricted stock agreement thereunder
−Removed: S-1/A 2/2/23 10.1
−Removed: 10.2# Mineralys Therapeutics, Inc.
−Removed: 2023 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder
−Removed: S-1/A 2/2/23 10.2
−Removed: 10.3# Mineralys Therapeutics, Inc.
−Removed: 2023 Employee Stock Purchase Plan
−Removed: S-1/A 2/2/23 10.3
−Removed: 10.4# Non-Employee Director Compensation Policy
−Removed: S-1/A 2/2/23 10.4
−Removed: 10.5#† Amended and Restated Employment Letter Agreement, dated February 1, 2023, by and between Jon Congleton and the Registrant
−Removed: S-1/A 2/2/23 10.5
−Removed: 10.6#† Amended and Restated Employment Letter Agreement, dated February 1, 2023, by and between David Rodman, M.D.
−Removed: and the Registrant
−Removed: S-1/A 2/2/23 10.6
−Removed: 10.7#† Amended and Restated Employment Letter Agreement, dated February 1, 2023, by and between Adam Levy and the Registrant
−Removed: S-1/A 2/2/23 10.7
−Removed: 10.8# Form of Indemnification Agreement for Directors and Officers
−Removed: S-1 1/18/23 10.8
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
__________________
−Removed: # Indicates management contract or compensatory plan.
−Removed: † Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601 of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.
* This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
1 unchanged sentence
MINERALYS THERAPEUTICS, INC.
−Removed: May 15, 2023 By:
+Added: August 7, 2023 By:
/s/ Jon Congleton
2 unchanged sentences
(Principal Executive Officer)
−Removed: May 15, 2023 By:
+Added: August 7, 2023 By:
/s/ Adam Levy
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.